Pharmaceutical pricing: who holds the cards now?

Negotiations between NHS England and Vertex over access to vital CF drugs have reached an impasse. Both sides appear to have dug their heels into the ground, with patients and politicians left frustrated at the prospect of yet more delays. Some are increasingly despondent over the prospect that a deal may never be reached. TheRead more

Drugpolitik: Trump’s pharma trade war puts medicines in the Brexit spotlight

Eighteen months into his Presidency, Donald Trump has finally found a saleable enemy for America’s high medical bills: ‘freeloading foreign governments.’ Healthcare costs often poll as one of the leading concerns of U.S. citizens, but Trump hasn’t been able to conjure a bogeyman who doesn’t infringe on the low-regulation, low-tax mantra of America First. UntilRead more

8 things you need to know about NICE’s changes to its appraisal process

The National Institute for Health and Care Excellence (NICE) has this week published its updated guide to its health technology appraisal (HTA) process following two rounds of consultations over the last six months. The aim of these changes is to streamline and accelerate the appraisal process. This consultation process has been very low key andRead more

Appraising vaccines in the UK – what’s worth a shot?

Ever since the first vaccination at the end of the 18th century (using fluid from a cowpox blister no less), the debate about vaccines has remained highly complex and emotive. The petition in the last parliament calling for wider access to the Meningitis B vaccination in the UK is the third largest petition the parliamentaryRead more

Can pharma get the right treatment? Brexit and the pharmaceutical industry

As Brexit draws closer, sectors are coming to terms with the implications of what separation may mean. The pharmaceutical industry was not one that attracted vast attention at the start of the negotiating process, with banking and farming taking up more column inches. However, as time has progressed the press, politicians and the sector itselfRead more

The Health Top Ten: Winter Edition

As the dark mornings set in and we all return to work, WA Health looks at the top ten trends, policy developments and potential pitfalls for the health sector to look out for in the run-up to Spring. New Year, New Me At this time of year many of us give ourselves New Year’s resolutionsRead more

Sector Deal or No Deal? The Verdict on the Government’s Plan for Life Sciences

The life sciences sector is the jewel in the crown of British industry and has been for some time. It outperforms all others in terms of productivity and growth, making it the teacher’s pet of the Industrial Strategy and a beacon for how industry and government can collaborate successfully on big-ticket issues such as genomicsRead more